NASDAQ:NGEN NervGen Pharma Q1 2026 Earnings Report $1.96 -0.11 (-5.31%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$2.03 +0.07 (+3.62%) As of 04:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast NervGen Pharma EPS ResultsActual EPS-$0.09Consensus EPS -$0.07Beat/MissMissed by -$0.02One Year Ago EPSN/ANervGen Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANervGen Pharma Announcement DetailsQuarterQ1 2026Date5/15/2026TimeAfter Market ClosesConference Call DateMonday, May 18, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) NervGen Pharma Earnings HeadlinesNervGen to Host Inaugural R&D Day on September 30, 2026September 9, 2026 | globenewswire.comNervGen Pharma Corp.: NervGen Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAugust 13, 2026 | finanznachrichten.deElon gets it. Do you?Moderna's stock jumped nearly 200% in a single day after a successful Phase 3 trial for its cancer drug, and Merck added $43 billion to its market cap on the same news. Porter & Co. says AI-driven drug discovery and automated labs are cutting development timelines by up to 80% and lifting early clinical success rates to 90%, fueling what they call biotech's Ignition Point.September 24 at 1:00 AM | Porter & Company (Ad)NervGen Pharma Posts Larger Q2 2026 Loss but Strengthens Cash PositionAugust 13, 2026 | tipranks.comNervGen Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAugust 13, 2026 | globenewswire.comNervGen Pharma Corp. : NGENJuly 13, 2026 | 247wallst.comSee More NervGen Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NervGen Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NervGen Pharma and other key companies, straight to your email. Email Address About NervGen PharmaNervGen Pharma (NASDAQ:NGEN) Corp. is a clinical-stage biotechnology company headquartered in Vancouver, British Columbia, focused on developing treatments that promote repair and recovery following damage to the nervous system. The company’s research is based on technology involving protein tyrosine phosphatase sigma, a receptor associated with the inhibition of nerve regeneration. NervGen’s lead product candidate is NVG-291, an investigational peptide designed to support neural repair, axonal regeneration and functional recovery. The company has been evaluating NVG-291 in clinical development for spinal cord injury and has also identified potential applications in conditions such as peripheral nerve injury and multiple sclerosis. Its programs are intended to address nervous-system damage for which existing treatment options are limited. The company’s development efforts build on research associated with scientists including Dr. Jerry Silver of Case Western Reserve University. NervGen conducts its corporate and clinical activities primarily from Canada while pursuing development opportunities and clinical research involving patients and institutions in North America. The company is led by President and Chief Executive Officer Mike Kelly.View NervGen Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
